Evidence-Based Medicine and the Problem of Healthy Volunteers
Journal Title: Annals of Hepatology - Year 2017, Vol 16, Issue 6
Abstract
Healthy controls are subjects without the disease being studied but may have other conditions indirectly affecting outcome. In the present epidemics of obesity a few subjects with undiagnosed nonalcoholic fatty liver disease enter clinical studies as controls, producing biased results. Stricter selection criteria should be considered to prevent this risk.
Authors and Affiliations
Giulio Marchesini, Francesca Marchignoli, Salvatore Petta
Keywords
Related Articles
- EP ID EP227994
- DOI 10.5604/01.3001.0010.5272
- Views 100
- Downloads 0
Gilbert’s syndrome and antiviral therapy of hepatitis C
Treatment of chronic hepatitis C with type I interferons and ribavirin can be associated with exacerbation of hepatitis and sometimes liver decompensation. We report two patients with chronic hepatitis C virus infection...
Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports
Introduction. Drug-induced liver injury (DILI) remains a major problem for drug development and represents a challenging diagnosis for clinicians. The absence of specific biomarkers for diagnosing DILI precludes the avai...
Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease
Background: Non-alcoholic fatty liver disease (NAFLD) is common in obese and diabetics. Serine protease inhibitor Kazal-1 (SPINK-1) protein is highly expressed in the liver and adipose tissue of diabetic and obese sugges...
Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction
Introduction. Endovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective...
Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with...